araag2/HINT huggingface dataset:
Clinical trial NCT01573351 (phase 3, status: completed)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: asunaprevir, daclatasvir, peg-interferon alfa-2a, ribavirin
SMILES: COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, ≥ 18 years of age

          -  HCV Genotype 1 or 4 who previously failed treatment with Peginterferon alfa-2a or
             peginterferon alfa-2b and Ribavirin (P/R), classified as previous null and partial
             responders based on previous therapy

          -  HCV RNA ≥ 10,000 IU/mL

          -  Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen
             (HBsAg)

          -  Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped
             at approximately 25% of treated population)

        Exclusion Criteria:

          -  Prior treatment of HCV with HCV direct acting antiviral (DAA)

          -  Evidence of a medical condition contributing to chronic liver disease other than HCV

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of ascites, bleeding varices, or hepatic encephalopathy

          -  Diagnosed or suspected hepatocellular carcinoma or other malignancies

          -  Uncontrolled diabetes or hypertension

          -  Total bilirubin ≥ 34 μmol/L (or ≥ 2 mg/dL) unless subject has a documented history of
             Gilbert's disease

          -  Alanine aminotransferase (ALT) ≥ 5x Upper limit of normal (ULN)

          -  Albumin < 3.5 g/dL (35 g/L)

          -  Alpha Fetoprotein (AFP) > 100 ng/mL (>82.6 IU/mL) or ≥ 50 and ≤ 100 ng/mL requires a
             liver ultrasound and subjects with findings suspicious of Hepatocellular carcinoma
             (HCC) are excluded

          -  Absolute neutrophil count (ANC) < 1.5 x 1000,000,000 cells/L (< 1.2 x 1000,000,000
             cells/L for Black/African-Americans)

          -  Platelets < 90 x 1000,000,000 cells/L

          -  Hemoglobin < 12 g/dL for females or < 13 g/dL for males

          -  Any criteria that would exclude the subject from receiving P/R
Clinical trial NCT00738530 (phase 3, status: completed)
Conditions: renal cell cancer
ICD codes: C96.20, C96.29, D47.09
Drugs: bevacizumab [avastin], interferon alfa 2a [roferon], placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  metastatic renal cell cancer (clear cell type);

          -  nephrectomy;

          -  absence of proteinuria.

        Exclusion Criteria:

          -  prior systemic treatment for metastatic renal cell cancer;

          -  major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to study treatment start;

          -  presence of brain metastases or spinal cord compression;

          -  ongoing need for full dose anticoagulants;

          -  uncontrolled hypertension;

          -  clinically significant cardiovascular disease.
Clinical trial NCT00321737 (phase 3, status: completed)
Conditions: esophagitis, reflux, esophagitis, peptic
ICD codes: K21.9, K21.00, K21.01, B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: dexlansoprazole mr, dexlansoprazole mr, placebo
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693)
             or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy.
             Complete healing was assessed for change in LA Esophagitis Classification grades A, B,
             C, or D to healed (defined as anything less than the criterion for Grade A). The
             subject was counted as healed if endoscopy findings did not meet the Grade A
             criterion.

        Exclusion Criteria:

          -  Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2)
             receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study.

          -  Use of antacids (except for study supplied) throughout the study.

          -  Use of drugs with significant anticholinergic effects such as tricyclics who cannot
             stay on a stable dose throughout the study.

          -  Chronic (>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or
             cyclo-oxygenase-2 (COX-2) inhibitors.

          -  Need for continuous anticoagulant therapy.

          -  Evidence of uncontrolled systemic disease.

          -  Subjects who have participated in either maintenance study (T-EE04-086 [NCT00255164]
             or T-EE04-087 [NCT00255151]).

          -  Subjects who, in the opinion of the investigator, is unable to comply with the
             requirements of the study or is unsuitable for any reason.
Clinical trial NCT00384072 (phase 3, status: completed)
Conditions: postmenopause, osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: bazedoxifene bza-20
SMILES: CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Generally healthy Asian women 45 years of age or older who are at least 1 year
             postmenopausal

          2. Subjects must qualify for one of the following categories (a or b):

               1. Greater than 1 year but less than 5 years postmenopausal with at least one of the
                  ospeoporosis risk factors

               2. Equal or greater than 5 years postmenopausal with BMD T-score at lumbar spine or
                  femoral neck between -1 and -2.5 (values of -1 and -2.5 are acceptable) with at
                  least one osteoporosis risk factor

        Exclusion Criteria:

          1. One (1) or more osteoporotic vertebral fractures (T4 - L4)

          2. BMD T-score at the lumbar spine or femoral neck less than -2.5

          3. Past history or active nontraumatic venous thromboembolic events, including deep vein
             thrombosis, pulmonary embolism, and retinal vein thrombosis
Clinical trial NCT01081769 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate injection, oral antipsychotics
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Have been meeting the diagnostic criteria for schizophrenia for 1 to 5 years before
             screening, and have a history of treatment with antipsychotics

          -  Have a history of two or more relapses requiring psychiatric hospitalization in the
             preceding 24 months, which may include the current acute episode

          -  Experiencing at screening an acute schizophrenic episode with a Positive And Negative
             Syndrome Scale (PANSS) total score at screening between 70 and 120, inclusive

          -  Be healthy on the basis of physical examination, medical history and vital signs
             performed at screening

          -  Woman must be postmenopausal (for at least 1 year) or surgically sterile or abstinent
             or be practicing an effective method of birth control, must agree to continue to use
             the same method of contraception throughout the study and must have a negative urine
             pregnancy test at screening

          -  be able to fill out questionnaires

          -  Men must agree to use a double barrier method of birth control and to not donate sperm
             during the study and for 3 months after receiving the last dose of study drug

        Exclusion Criteria:

          -  Patients that have never been treated with antipsychotics before

          -  Treatment resistant patient and/or currently (i.within the last 3 months) treated with
             clozapine

          -  Substance dependence within 6 months prior to entry and current intravenous drug use
             or abuse

          -  allergies, hypersensitivity, or intolerance to risperidone or paliperidone or
             excipients

          -  treatment with a long-acting injectable antipsychotic within three injection cycles
             prior to screening

          -  newly started psychotherapy program within the two months preceding the treatment
             phase baseline

          -  evidence of clinically significant hepatic, renal, cardiac, vascular, pulmonary,
             gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or
             metabolic disturbances in the past 6 months (as determined by medical history,
             clinical laboratory or ECG results, or physical examination) that would increase the
             risk associated with taking study medication or would confound the interpretation of
             the study

          -  history or current symptoms of tardive dyskinesia or neuroleptic malignant syndrome

          -  involuntarily hospitalized patient

          -  pregnant or breast-feeding females
Clinical trial NCT01241760 (phase 3, status: completed)
Conditions: genotype 1 chronic hepatitis c, treatment naive
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ribavirin, telaprevir, pegylated interferon alfa-2a, telaprevir
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has chronic HCV infection genotype 1 with HCV RNA level > 1,000 IU/mL

          -  Patients should not have had any previous treatment for hepatitis C

          -  Patient must have documentation of a liver biopsy within 2 years before the screening
             visit or the patient must agree to have a biopsy performed within the screening period

          -  Patients with cirrhosis should have serum alpha-fetoprotein (AFP) <= 50 ng/mL. If AFP
             > 50 ng/mL, absence of a mass must be demonstrated by ultrasound within the screening
             period

          -  A female patient of childbearing potential and a nonvasectomized male patient who has
             a female partner of childbearing potential must agree to the use of 2 effective
             methods of birth control from screening until 6 months (female patient) or 7 months
             (male patient) after the last dose of RBV.

        Exclusion Criteria:

          -  Patient is infected or co-infected with HCV of another genotype than genotype 1 and/or
             patient is infected with more than one genotype subtype

          -  Patient has a pre-existing psychiatric condition

          -  Patient has history of decompensated liver disease or shows evidence of significant
             liver disease in addition to hepatitis C

          -  Patient has human immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection

          -  Patient has active malignant disease or history of malignant disease within the past 5
             years (with the exception of treated basal cell carcinoma).
Clinical trial NCT00300482 (phase 3, status: completed)
Conditions: dyslipidemia, coronary heart disease, mixed dyslipidemia
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: abt-335, rosuvastatin calcium, placebo
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mixed dyslipidemia

        Exclusion Criteria:

          -  Subjects with unstable medical conditions or medical conditions considered
             inappropriate in a clinical trial.

          -  Patients who are taking certain medications or unstable dose of specific medications.

          -  Women who are pregnant or plan on becoming pregnant or women who are lactating.
Clinical trial NCT00004054 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, luteinizing hormone releasing hormone [lhrh] agonist, warfarin
SMILES: [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H], OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC(C)C(=O)NC1=CC(=C(C=C1)[N+]([O-])=O)C(F)(F)F, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, S1SSSSSSS1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven prostate cancer at high risk for relapse as determined by either
             of the following:

               -  Prostate-specific antigen (PSA) 20-100 ng/mL and Gleason score at least 7 (any T
                  stage)

               -  Clinical stage at least T2, Gleason score at least 8, and PSA no greater than 100
                  ng/mL

          -  Negative lymph nodes

          -  No metastatic disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  Zubrod 0 or 1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  White blood cell (WBC) count of at least 3,000/mm^3

          -  Platelet count at least 130,000/mm^3

          -  Hemoglobin at least 11.4 g/dL

        Hepatic:

          -  Aspartate aminotransferase (AST) no greater than 2 times upper limit of normal

        Renal:

          -  Creatinine no greater than 2.5 mg/dL

        Other:

          -  No other invasive cancer within the past 5 years except superficial nonmelanomatous
             skin cancer

          -  No major medical or psychiatric illness that would preclude study participation

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 5 years since prior chemotherapy

        Endocrine therapy:

          -  At least 60 days since prior finasteride for prostatic hypertrophy

          -  At least 90 days since prior testosterone

          -  No more than 30 days since initiation of prior pharmacologic androgen ablation for
             prostate cancer

        Radiotherapy:

          -  No prior pelvic radiotherapy

          -  No concurrent intensity-modulated radiotherapy

        Surgery:

          -  No prior radical prostatectomy

          -  No prior cryosurgery for prostate cancer

          -  No prior orchiectomy
Clinical trial NCT00262600 (phase 3, status: completed)
Conditions: atrial fibrillation, stroke
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, G46.4, G46.3, Z82.3
Drugs: warfarin, dabigatran dose 1, dabigatran dose 2
SMILES: S1SSSSSSS1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
Eligibility criteria:

        Inclusion criteria Patients with non-valvular atrial fibrillation (AF), at moderate to high
        risk of stroke, or systemic embolism with at least one additional risk factor (i.e.
        previous ischemic stroke, TIA, or systemic embolism, left ventricular dysfunction, age >=75
        years, age >=65 with either diabetes mellitus, history of coronary artery disease or
        hypertension)

        Exclusion criteria

          1. Prosthetic heart valves requiring anticoagulation per se, or hemodynamically relevant
             valve disease that is expected to require surgical intervention during the course of
             the study

          2. Severe, disabling stroke within the previous 6 months, or any stroke within the
             previous 14 days

          3. Conditions associated with an increased risk of bleeding

          4. Contraindication to warfarin treatment

          5. Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism,
             untreated hyperthyroidism).

          6. Plan to perform a pulmonary vein ablation or surgery for cure of the AF

          7. Severe renal impairment (estimated creatinine clearance <=30 mL/min)

          8. Active infective endocarditis

          9. Active liver disease

         10. Women who are pregnant, lactating, or of childbearing potential who refuse to use a
             medically acceptable form of contraception throughout the study

         11. Anaemia (haemoglobin <100g/L) or thrombocytopenia (platelet count <100 x 109/L)

         12. Patients who have developed transaminase elevations upon exposure to ximelagatran

         13. Patients who have received an investigational drug in the past 30 days or are
             participating in another drug study

         14. Patients considered unreliable by the investigator concerning the requirements for
             follow-up during the study and/or compliance with study drug administration, has a
             life expectancy less than the expected duration of the trial due to concomitant
             disease, or has any condition which in the opinion of the investigator, would not
             allow safe participation in the study (e.g., drug addiction, alcohol abuse)

         15. Any known hypersensitivity to galactose if the warfarin used contains galactose.
Clinical trial NCT01384292 (phase 3, status: terminated)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: nktr-118, nktr-118, placebo
SMILES: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was stopped early due to recruitment challenges
  
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent prior to any study-specific procedures.

          -  Men and women aged 18 or older.

          -  Histologically or cytologically confirmed neoplasm causing pain and requiring
             management with opioids.

          -  Self-reported active symptoms of OIC at screening (<3 RFBMs/week and experiencing >1
             reported symptom of hard/lumpy stools, straining, or sensation of incomplete
             evacuation/anorectal obstruction in at least 25% of BMs over the previous 4 weeks);
             and Documented confirmed OIC (<3 RFBMs/week on average aver the 2-week OIC
             confirmation period.

          -  Receiving a stable maintenance opioid regimen consisting of a total daily dose of >30
             mg of oral morphine, or equianalgesic amount(s) of 1 or more opioid therapies for a
             minimum of 4 weeks prior to screening for cancer-related pain with no anticipated
             change in opioid dose requirement over the proposed study period as a result of
             disease progression.

        Exclusion Criteria:

          -  Patients receiving Opioid regimen for treatment of pain other than related to cancer.

          -  Any condition that may have affected the permeability of the blood-brain barrier, eg,
             known brain metastases, meningeal metastases, brain injury, multiple sclerosis, recent
             brain injury, uncontrolled epilepsy.

          -  Patients with cancer-related pain due to ovarian cancer, leukaemia, or lymphoma are
             excluded. Patients with multiple myeloma will be allowed.

          -  Patients requiring radiation therapy between the diaphragm and pelvis 4 weeks prior to
             Visit 1 (screening) and/or during Part A of the study are excluded. Any patients with
             suspected clinically relevant radiation-induced injury of small or large intestine are
             excluded.

          -  Pregnancy or lactation.
Clinical trial NCT00679900 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: eplivanserin (sr46349), lormetazepam
SMILES: CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)/C1=CC=CC=C1F, OC1N=C(C2=CC=CC=C2Cl)C2=C(NC1=O)C=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Primary Insomnia according to Diagnostic and Statistical Manual of Mental Disorders
             (DSM-IV-TR) criteria

          -  At least 1 hour of wakefulness for at least 3 nights per week during the month
             preceding inclusion

          -  Disturbances of sleep maintenance criteria based on the patient's sleep questionnaire
             during the run-in period

        Exclusion Criteria:

          -  Pregnant or breastfeeding women and women of childbearing potential without effective
             contraceptive method of birth control

          -  Night shift workers and individuals who nap 3 or more times per week

          -  Consumption of xanthine-containing beverages (i.e., tea, coffee or cola) that
             comprises more than 5 cups or glasses per day

          -  Insomnia secondary to a general medical condition

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00457392 (phase 3, status: completed)
Conditions: carcinoma, non-small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: erlotinib, sunitinib, erlotinib, placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with locally advanced/metastatic non-small cell lung cancer

          -  Prior treatment with no more than 2 chemotherapy regimens including a platinum-based
             regimen

        Exclusion Criteria:

          -  Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the
             exception of bevacizumab) or other angiogenesis inhibitors

          -  History of or known brain metastases